Fideuram Asset Management Ireland dac Makes New $681,000 Investment in IDEXX Laboratories, Inc. $IDXX

Fideuram Asset Management Ireland dac bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 1,007 shares of the company’s stock, valued at approximately $681,000.

Several other hedge funds have also recently bought and sold shares of IDXX. Empowered Funds LLC raised its holdings in IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after buying an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $265,000. Jump Financial LLC raised its holdings in IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after buying an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $164,000. Finally, Sei Investments Co. raised its holdings in IDEXX Laboratories by 218.7% during the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after buying an additional 82,755 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $563.53 on Friday. The company has a market cap of $44.45 billion, a price-to-earnings ratio of 41.50, a PEG ratio of 3.27 and a beta of 1.58. IDEXX Laboratories, Inc. has a 1-year low of $504.56 and a 1-year high of $769.98. The company’s fifty day simple moving average is $564.58 and its 200 day simple moving average is $637.19. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the transaction, the executive vice president directly owned 18,141 shares of the company’s stock, valued at $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.79% of the stock is currently owned by company insiders.

Analyst Ratings Changes

IDXX has been the topic of a number of recent research reports. BTIG Research lowered their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Barclays lowered their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Piper Sandler lowered their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. UBS Group lowered their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Finally, Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.